Molecular profiling and companion diagnostics: where is personalized medicine in cancer heading?

2014 ◽  
Vol 11 (8) ◽  
pp. 761-771 ◽  
Author(s):  
Mukesh Verma
2020 ◽  
Author(s):  
Melissa Lucero ◽  
Jefferson Chan

<p>Companion diagnostics (CDx) represent a new frontier in personalized medicine that promises to improve treatment outcomes by matching therapies to patients. Currently, these tests are limited in scope and cannot report on real-time changes associated with disease progression and remediation. To address this, we have developed the first photoacoustic imaging-based CDx (PACDx) for the selective detection of elevated glutathione (GSH) in lung cancer. Since GSH is abundant in most cells, we utilized a physical organic approach to precisely tune the chemical reactivity to distinguish between normal and pathological states. In blinded studies, PACDx was applied to identify mice bearing lung tumors. Moreover, we designed a matching prodrug, PARx, that utilizes the same mechanism to release a chemotherapeutic with a PA readout. We demonstrate that PARx can inhibit tumor growth without off-target toxicity in a lung cancer xenograft model. We envision that this work will establish a new standard for personalized medicine by employing a unique imaging-based approach.<br></p>


Author(s):  
Pieter-Jan van Dam ◽  
Steven Van Laere

Recent efforts by worldwide consortia such as The Cancer Genome Atlas and the International Cancer Genome Consortium have greatly accelerated our knowledge of human cancer biology. Nowadays, complete sets of human tumours that have been characterized at the genomic, epigenomic, transcriptomic, or proteomic level are available to the research community. The generation of these data was made possible thanks to the application of high-throughput molecular profiling techniques such as microarrays and next-generation sequencing. The primary conclusion from current profiling experiments is that human cancer is a complex disease characterized by extreme molecular heterogeneity, both between and within the classical, tissue-defined cancer types. This molecular variety necessitates a paradigm shift in patient management, away from generalized therapy schemes and towards more personalized treatments. This chapter provides an overview of how molecular cancer profiling can assist in facilitating this transition. First, the state-of-the-art of molecular breast cancer profiling is reviewed to provide a general background. Then, the most pertinent high-throughput molecular profiling techniques along with various data mining techniques (i.e. unsupervised clustering, statistical learning) are discussed. Finally, the challenges and perspectives with respect to molecular cancer profiling, also from the perspective of personalized medicine, are summarized.


2015 ◽  
Vol 49 (4) ◽  
pp. 530-543 ◽  
Author(s):  
Marilyn Tsourounis ◽  
Jeffrey Stuart ◽  
William Pignato ◽  
Michael Toscani ◽  
Joseph Barone

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 5578-5578 ◽  
Author(s):  
Ana C. Garrido-Castro ◽  
Guillem Argilés ◽  
Debora Moreno ◽  
Victor Rodriguez-Freixinos ◽  
Marta Vilaro ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document